Prostate Cancer: A Urologic Oncology Perspective
Prostate cancer is the most commonly diagnosed cancer in men, yet it's highly heterogeneous. Some men have indolent disease that progresses slowly, while others develop aggressive cancers requiring immediate intervention. As a urologic oncologist, Dr. Libby specializes in risk stratification and personalized treatment planning to distinguish which cancers require aggressive treatment and which benefit from surveillance.
Screening Guidelines and Risk Factors
Contemporary prostate cancer screening guidelines emphasize informed decision-making. Men aged 50-69 with average risk should discuss screening benefits and risks with their physician. African American men and those with a family history of prostate cancer face higher risk and may benefit from earlier screening discussions beginning at age 40-45. Genetic testing for high-risk mutations is recommended for certain men. Dr. Libby helps patients understand their individual risk profile and make informed decisions about screening and prevention.
Risk Stratification
Once diagnosed, prostate cancer is stratified into risk categories based on PSA level, Gleason score, and clinical stage. Low-risk cancers often remain localized and may grow very slowly. Intermediate-risk cancers require careful monitoring and may warrant treatment. High-risk and very-high-risk cancers have significant metastatic potential and typically require aggressive multimodal therapy. This stratification guides treatment decisions and prognostication.
Active Surveillance in Low-Risk Disease
Many men with low-risk prostate cancer never require treatment and do well with active surveillance. This approach includes regular PSA testing, digital rectal exams, and periodic biopsies to confirm cancer remains low-risk. Active surveillance avoids treatment-related side effects in men whose cancers would never progress to cause harm. Dr. Libby carefully monitors surveillance patients using validated protocols to ensure safety while sparing unnecessary treatment.
Curative Treatment Options
Radical Prostatectomy
For localized disease, robotic-assisted radical prostatectomy offers excellent oncologic outcomes with lower morbidity than open surgery. Dr. Libby's expertise in robotic surgery enables precise cancer removal while preserving continence and erectile function when possible. Extended pelvic lymph node dissection is performed in intermediate and high-risk patients to assess for nodal metastases.
External Beam Radiation Therapy
Modern intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) offer effective treatment with acceptable toxicity profiles. For intermediate-risk disease, combining radiation with hormone therapy improves outcomes.
Brachytherapy
Low-dose-rate and high-dose-rate brachytherapy are effective options for appropriately selected patients, often combined with external beam radiation.
Multidisciplinary Care Coordination
Optimal prostate cancer treatment often requires coordinated care among urologists, radiation oncologists, and medical oncologists. Dr. Libby collaborates with these specialists to develop comprehensive treatment plans tailored to each patient's cancer characteristics, age, comorbidities, and preferences.
Advanced and Metastatic Disease
For patients with locally advanced cancer at high risk for metastatic spread, neoadjuvant hormone therapy combined with radiation or surgery improves outcomes. For castration-resistant metastatic prostate cancer, newer hormonal agents, chemotherapy, and immunotherapy have dramatically improved survival. Dr. Libby works closely with medical oncology colleagues to coordinate these complex treatment plans.
Side Effect Management
Erectile dysfunction and urinary incontinence are potential side effects of prostate cancer treatment. Dr. Libby discusses prevention and management strategies before treatment and provides comprehensive support, including medications, devices, and referrals to specialists, to maintain quality of life.
Referral for Urologic Oncology Consultation
Patients with newly diagnosed prostate cancer, recurrent disease, or complex clinical scenarios benefit from urologic oncology consultation. If your primary care physician or another urologist has recommended prostate cancer evaluation, Dr. Libby provides comprehensive assessment and personalized treatment recommendations.
Prostate Cancer Surveillance and Follow-Up
After treatment, regular surveillance with PSA testing and clinical exams monitors for recurrence. Biochemical recurrence (rising PSA) is detected earlier than imaging evidence of metastases and requires prompt evaluation and potential salvage therapy. Dr. Libby provides meticulous long-term follow-up to optimize cancer control and quality of life.